Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02259803
Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02259816
Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02259829
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02259790
The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02233218
- Locations
- 🇰🇷
Dong-A university hospital, Pusan, Korea, Republic of
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT02213224
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong, China
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 456
- Registration Number
- NCT02206165
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT02205151
- Locations
- 🇰🇷
The Catholic university St. Mary hospital, Seoul, Korea, Republic of
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02194309
Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02193308
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.